Hyperaldosteronism is a disorder that is characterized by the excessive release of aldosterone into the blood and is a common cause of secondary hypertension. The main goals of treatment are the normalization of blood pressure, as well as levels of aldosterone, potassium, and other electrolytes. Appropriate treatment depends on the cause, with surgical excision of the affected adrenal gland recommended for certain patients. However, most hyperaldosteronism patients are treated primarily with an aldosterone antagonist. Additional antihypertensive agents are commonly prescribed in patients whose blood pressure remains above normal. Treatment in this market is well entrenched with generic options available for most of the drug classes used. The Hyperaldosteronism Treatment Algorithm provides insights into drug class prescribing patterns among a wealth of treatment options, where owing to the high availability of generics, pricing pressures are of minimal concern.

QUESTIONS ANSWERED 

  • What patient share do key drug classes garner by line of therapy in newly diagnosed hyperaldosteronism patients?
  • What are the quarterly trends in prescribing among recently-treated and new diagnosed hyperaldosteronism patients?
  • How is patient share distributed across the renin-angiotensin-aldosterone system (RAAS) inhibitors now that generic options are widely available?
  • What proportion of hyperaldosteronism patients receive drug therapy within one year of diagnosis, and how quickly?
  • What percentage of patients progress to later lines of therapy within one year of diagnosis?
  •  What percentage of hyperaldosteronism patients are treated with monotherapy versus combination therapy?
  • What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with hyperaldosteronism?